Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

This study found that a topical henna formulation may improve symptoms like itching, burning, and redness in patients with recessive dystrophic epidermolysis bullosa, but larger controlled studies are needed.

This review discusses the limited treatment options for androgenetic alopecia, alopecia areata, and chemotherapy-related alopecia, reporting no new clinical findings.

This study found that while there were no significant differences in ovulation and pregnancy rates, chromium picolinate was better tolerated than metformin in women with polycystic ovarian syndrome.

This study found that 2.2% minoxidil gel was more effective than placebo in treating alopecia areata and reported similar safety outcomes between the two groups.

This study found that oral finasteride was more effective than topical 3% minoxidil Co. for treating androgenetic alopecia in Chinese men over a six-month period.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This review reports that while ginseng's safety profile seems favorable, the evidence for its clinical efficacy remains limited due to generally poor study quality in the included Korean randomized trials.

This study found that topically applied minoxidil was more effective than nitroglycerin and placebo in enhancing penile diameter, rigidity, and arterial flow, with the most pronounced effects in patients with neurogenic impotence.

This review examines the use and efficacy of Panax ginseng in various clinical settings, noting that clinical trial outcomes vary widely based on study conditions and ginseng types; no new results are reported.

This review discusses the challenges of using surrogate variables versus primary clinical end-points in PCOS trials and reports no new research results; the authors suggest focusing future studies on primary outcomes.

In this study, divalproex sodium extended-release was found to be more tolerable and preferred by patients compared to the delayed-release formulation, with improved seizure control and psychiatric symptom relief.

This study suggests a possible link between late puberty onset and decreased prostate cancer risk, while over-the-counter ibuprofen use was associated with increased risk.

This study found that platelet-rich plasma was effective for hair regrowth in women with androgenic alopecia, though less so than minoxidil, but it was associated with improved quality of life responses.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that transplantation of autologous stromal vascular fraction cells increased skin thickness and improved regeneration when combined with mechanical stretching, without severe adverse events.

In this study, cimetidine at a daily dose of 1.5 gm for 3 months did not significantly affect hair growth in women with moderate to severe hirsutism.

This source observed that while supplementation with pro-, pre-, and synbiotics showed some beneficial effects for PCOS-related outcomes, the evidence quality was deemed low to very low, highlighting the need for further well-designed randomized controlled trials in women with PCOS.

This paper discusses the methods and challenges of postmarketing surveillance for new antiepileptic drugs, emphasizing the necessity of such data collection to identify adverse effects and assess drug effectiveness beyond initial trials.

This study found that FDA-approved low-level light/laser therapy devices significantly increased hair density in individuals with pattern hair loss compared to sham devices.

This study developed a standardized strategy using blinded expert panel reviews of home videos to assess developmental milestones in infants with neurodegenerative diseases, finding it to be feasible, meaningful, and preferred by parent/caregivers compared to in-clinic assessments.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study reports that discrepancies in adverse event reporting for clinical blood pressure trials undermine the reliability of safety data, suggesting a need for standardized reporting guidelines to improve trustworthiness.

This study observed that topical prostaglandin treatments may protect against hair follicle injury during chemotherapy, as indicated by preserved eyelashes in patients using these treatments.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

The review concluded that better studies are needed to prove if Low-Level Laser Therapy devices for hair growth really work.

This study reported that among obese women with PCOS, neither early time-restricted eating (eTRE) alone nor combined with probiotics showed significant improvements in blood pressure, inflammatory markers, oxidative stress, or antioxidant capacity compared to a standard reduced-calorie diet.

This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.